Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Erasca, Inc.
  6. Summary
    ERAS   US29479A1088

ERASCA, INC.

(ERAS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
20.44(c) 20.83(c) 21.04(c) 20.61(c) 19.42(c) Last
282 955 302 539 271 910 269 315 3 780 283 Volume
-2.76% +1.91% +1.01% -2.04% -5.77% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -133 M - -
Net cash position 2021 90,8 M - -
P/E ratio 2021 -6,36x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -239 M - -
Net cash position 2022 89,8 M - -
P/E ratio 2022 -5,28x
Yield 2022 -
Capitalization 2 354 M 2 354 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 102
Free-Float 67,3%
More Financials
Company
Erasca, Inc is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company is engaged in oncology and RAS targeting to create therapies and combination regimens for the treatment of cancer. Its product candidates are ERAS-007 and ERAS-601, which together comprises its MAPKlamp. In... 
More about the company
All news about ERASCA, INC.
09/09ERASCA : Doses First Patient in Lung Cancer Treatment Trial
MT
09/09Erasca Announces First Patient Dosed in HERKULES-2 Phase 1b/2 Lung Cancer Mas..
GL
09/09Erasca Announces First Patient Dosed in HERKULES-2 Phase 1b/2 Lung Cancer Mas..
CI
09/08ERASCA : Pfizer Collaborate on Colorectal Cancer Combo Therapy
MT
09/08Erasca in Clinical Trial Collaboration Agreement With Pfizer
DJ
09/08PFIZER : Erasca Announces Clinical Trial Collaboration and Supply Agreement with..
AQ
09/02ERASCA : to Participate in the Morgan Stanley 19th Annual Global Healthcare Virt..
AQ
08/27ERASCA : Reports Second Quarter 2021 Financial Results and Business Updates (For..
PU
08/26ERASCA : Q2 Loss Widens, Operating Expenses Rise
MT
08/26ERASCA : Management's Discussion and Analysis of Financial Condition and Results..
AQ
08/26ERASCA, INC. : Results of Operations and Financial Condition, Financial Statemen..
AQ
08/26Erasca Reports Second Quarter 2021 Financial Results and Business Updates
GL
08/26ERASCA : Reports Second Quarter 2021 Financial Results and Business Updates
AQ
08/26ERASCA : Earnings Flash (ERAS) ERASCA Posts Q2 Loss $-1.20
MT
08/26Erasca, Inc. Reports Unaudited Consolidated Earnings Results for the Second Q..
CI
More news
News in other languages on ERASCA, INC.
09/09Erasca administre une dose au premier patient d'un essai de traitement du can..
09/08Erasca et Pfizer collaborent sur une bithérapie contre le cancer colorectal
08/26La perte d'Erasca au deuxième trimestre se creuse, les dépenses d'exploitatio..
08/26Earnings Flash (ERAS) ERASCA affiche une perte au 2ème trimestre $-1.20
More news
Analyst Recommendations on ERASCA, INC.
More recommendations
Chart ERASCA, INC.
Duration : Period :
Erasca, Inc. Technical Analysis Chart | ERAS | US29479A1088 | MarketScreener
Technical analysis trends ERASCA, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 19,42 $
Average target price 30,20 $
Spread / Average Target 55,5%
EPS Revisions
Managers and Directors
Jonathan E. Lim Chairman & Chief Executive Officer
David M. Chacko Chief Financial Officer
Michael D. Varney Director, Chairman-Research & Development
Wei Lin Chief Medical Officer
Nik Chetwyn Senior Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ERASCA, INC.0.00%2 354
MODERNA, INC.311.65%173 588
LONZA GROUP AG32.35%60 074
IQVIA HOLDINGS INC.43.07%49 116
CELLTRION, INC.-23.26%31 904
SEAGEN INC.-10.81%28 420